135 related articles for article (PubMed ID: 8317329)
1. Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers.
Zielinski T; Müller HJ; Bartlett RR
Agents Actions; 1993; 38 Spec No():C80-2. PubMed ID: 8317329
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
3. Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide.
Mirmohammadsadegh A; Homey B; Abts HF; Köhrer K; Ruzicka T; Michel G
Biochem Pharmacol; 1998 May; 55(9):1523-9. PubMed ID: 10076546
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of anti-CD3 antibody-induced mouse T cell activation by pentoxifylline in combination with rapamycin or A77 1726 (leflunomide).
Richard M; Hoskin DW
Int J Immunopharmacol; 1998; 20(4-5):241-52. PubMed ID: 9730259
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.
Mattar T; Kochhar K; Bartlett R; Bremer EG; Finnegan A
FEBS Lett; 1993 Nov; 334(2):161-4. PubMed ID: 8224241
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction.
Hoskin DW; Taylor RM; Makrigiannis AP; James H; Lee TD
Int J Immunopharmacol; 1998 Sep; 20(9):505-13. PubMed ID: 9818794
[TBL] [Abstract][Full Text] [Related]
7. The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis.
Vrenken TE; Buist-Homan M; Kalsbeek AJ; Faber KN; Moshage H
J Hepatol; 2008 Nov; 49(5):799-809. PubMed ID: 18809221
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury.
Morris RE; Huang X; Cao W; Zheng B; Shorthouse RA
Transplant Proc; 1995 Feb; 27(1):445-7. PubMed ID: 7879056
[No Abstract] [Full Text] [Related]
9. Inhibition of HIV replication by A77 1726, the active metabolite of leflunomide, in combination with pyrimidine nucleoside reverse transcriptase inhibitors.
Hossain MM; Margolis DM
J Acquir Immune Defic Syndr; 2001 Oct; 28(2):199-201. PubMed ID: 11588518
[No Abstract] [Full Text] [Related]
10. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Greene S; Watanabe K; Braatz-Trulson J; Lou L
Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.
Manna SK; Aggarwal BB
J Immunol; 1999 Feb; 162(4):2095-102. PubMed ID: 9973483
[TBL] [Abstract][Full Text] [Related]
12. The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha.
Magne D; Mézin F; Palmer G; Guerne PA
Inflamm Res; 2006 Nov; 55(11):469-75. PubMed ID: 17122964
[TBL] [Abstract][Full Text] [Related]
13. [Leflunomide inhibits PAF induced DNA synthesis in rabbit synovial cells and PAF production from rat peritoneal macrophages].
Ju DW; Zheng QY; Wang HB; Fang J
Yao Xue Xue Bao; 1994; 29(2):90-4. PubMed ID: 8042517
[TBL] [Abstract][Full Text] [Related]
14. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes.
Burger D; Begué-Pastor N; Benavent S; Gruaz L; Kaufmann MT; Chicheportiche R; Dayer JM
Rheumatology (Oxford); 2003 Jan; 42(1):89-96. PubMed ID: 12509619
[TBL] [Abstract][Full Text] [Related]
15. Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes.
Vergne-Salle P; Léger DY; Bertin P; Trèves R; Beneytout JL; Liagre B
Cytokine; 2005 Sep; 31(5):335-48. PubMed ID: 16099671
[TBL] [Abstract][Full Text] [Related]
16. In vivo lymphoproliferation in the popliteal lymph node (PLN) assay can be inhibited by leflunomide's active metabolite A77 1726.
Schorlemmer HU; Kurrle R; Schleyerbach R; Bartlett RR
Inflamm Res; 1999 Dec; 48 Suppl 2():S111-2. PubMed ID: 10667839
[No Abstract] [Full Text] [Related]
17. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Rückemann K; Fairbanks LD; Carrey EA; Hawrylowicz CM; Richards DF; Kirschbaum B; Simmonds HA
J Biol Chem; 1998 Aug; 273(34):21682-91. PubMed ID: 9705303
[TBL] [Abstract][Full Text] [Related]
18. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Moon SJ; Kim EK; Jhun JY; Lee HJ; Lee WS; Park SH; Cho ML; Min JK
J Transl Med; 2017 Feb; 15(1):31. PubMed ID: 28193225
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay.
Slauson SD; Silva HT; Sherwood SW; Morris RE
Immunol Lett; 1999 Apr; 67(3):179-83. PubMed ID: 10369124
[TBL] [Abstract][Full Text] [Related]
20. Modulation of human peripheral blood mononuclear cell activation by the combination of leflunomide and pentoxifylline.
Stojic Vukanic Z; Dimitrijevic M; Colic M; Popovic P; Jandric D
Transplant Proc; 2001 May; 33(3):2137-8. PubMed ID: 11377478
[No Abstract] [Full Text] [Related]
[Next] [New Search]
